Recombinant CD44 antibody (full length)

Catalog No. ABIN7877885

This Rabbit Monoclonal antibody specifically detects CD44 in IHC (p). It exhibits reactivity toward Human.

Quick Overview for Recombinant CD44 antibody (full length) (ABIN7877885)

Target: CD44

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This CD44 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: HCAM-6459R

Product Details anti-CD44 Antibody

Binding Specificity: full length

Purpose: Recombinant CD44 Antibody / HCAM (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human CD44 protein was used as the immunogen for the recombinant CD44 antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the recombinant CD44 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the recombinant CD44 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for CD44

Target: CD44

Alternative Name: CD44

Background: Recognizes a cell surface glycoprotein of 80-95 kDa (CD44) on lymphocytes, monocytes, and granulocytes (Leucocyte Typing Workshop V). Its epitope is resistant to digestion by trypsin and chymotrypsin. This MAb selectively interferes with lymphocyte binding to lymph node, mucosal and synovial endothelium. The CD44 family of glycoproteins exists in a number of variant isoforms, the most common being the standard 85-95 kDa or hematopoietic variant (CD44s). Higher molecular weight isoforms are described in epithelial cells (CD44v), which are believed to function in intercellular adhesion and stromal binding. CD44 immunostaining is commonly used for the discrimination of urothelial transitional cell carcinoma in-situ from non-neoplastic changes in the urothelium.

UniProt: P16070

Pathways: Glycosaminoglycan Metabolic Process, Autophagy, Negative Regulation of intrinsic apoptotic Signaling